Shares of Hims & Hers Health Inc. (HIMS) plummeted 25.76% in the pre-market trading session on Friday, after the U.S. Food and Drug Administration announced that the shortage of Novo Nordisk's popular weight-loss and diabetes drugs Ozempic and Wegovy has been resolved.
The resolution of the shortage could potentially restrict how telehealth programs like Hims & Hers offer cheaper versions known as compounded drugs, which have seen a boom in demand due to the tight supply of Novo Nordisk's treatments. Regulations allow compounding pharmacies to copy brand-name medicines only when they are in short supply.
With the shortage ending, companies offering compounded versions of semaglutide, the active ingredient in Ozempic and Wegovy, could face challenges. This development poses a threat to Hims & Hers, which offers compounded semaglutide as an alternative to the brand-name drugs.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。